Applications for this meeting must be submitted by February 1, 2014. Please apply early, as some meetings become oversubscribed (full) before this deadline. If the meeting is oversubscribed, it will be stated here. Note: Applications for oversubscribed meetings will only be considered by the Conference Chair if more seats become available due to cancellations.
GRS Speaker Abstract Deadline: Although applications will be accepted until the date noted above, any applicants who wish to be considered for an oral presentation should submit their application by December 1, 2013. Please refer to the Application Instructions section below for more details (if available).
The Angiotensin Gordon Research Seminar will be held in conjunction with the Angiotensin Gordon Research Conference
. Those interested in attending both meetings must submit an application for the GRC in addition to an application for the GRS. Please refer to the Angiotensin GRC web page for more information.
The Gordon Research Seminar on Angiotensin is a unique forum for graduate students, post-docs, and other scientists with comparable levels of experience and education to present and exchange new data and cutting edge ideas.
The focus of this meeting will be on therapies targeting the new components of the RAS; bridging the gap between basic research and clinical efficacy in pathological conditions, such as in diabetes and obesity, hypertension, aging, heart and renal failure, and auto-immune diseases.
The meeting will feature approximately 10 talks and 2 poster sessions. All attendees are expected to actively participate in the GRS either by giving an oral presentation or presenting a poster. Therefore, all applications must include an abstract.
The Chairs will select speakers from abstracts submitted by December 1, 2013. Those applicants who are not chosen for talks and those who apply after the deadline to be considered for an oral presentation will be expected to present a poster. In order to participate, you must submit an application by the date indicated in the Application Deadline section above.
|1:30 pm - 4:30 pm||Arrival and Check-in|
|3:00 pm - 3:15 pm||Introductory Comments by GRC Site Staff / Welcome by the GRS Conference Chair|
|3:15 pm - 4:00 pm||Keynote Session|
|Discussion Leader: TBA|
|3:15 pm - 3:45 pm||Dominik Mueller (Max-Delbruck-Centrum, Berlin, Germany)
"Unpredictable Results - The Big Chance in Science"
|3:45 pm - 4:00 pm||Discussion|
|4:00 pm - 5:30 pm||Poster Session I|
|5:30 pm - 7:30 pm||The RAS and Diabetes|
|Discussion Leaders: Rajesh Kumar and Candice Thomas (Texas A&M Health Science Center, Temple, TX)|
|5:30 pm - 5:50 pm||Candice Thomas (Texas A&M Health Science Center)|
|5:50 pm - 6:00 pm||Discussion|
|6:00 pm - 6:20 pm||Katrina Binger (Max-Delbrueck Center for Molecular Medicine, Berlin, Germany)
"(Pro)renin receptor conditional knockout causes beta-cell loss and hyperglycemia by inducing pathological autophagy"
|6:20 pm - 6:30 pm||Discussion|
|6:30 pm - 6:50 pm||Robin Shoemaker (Graduate Center for Nutritional Sciences, University of Kentucky)
"ACE2 deficiency augments the development of type 2 diabetes in obese mice"
|6:50 pm - 7:00 pm||Discussion|
|7:00 pm - 7:20 pm||TBA|
|7:20 pm - 7:30 pm||Discussion|
|7:30 am - 8:30 am||Breakfast|
|9:00 am - 11:00 am||New therapeutics for the RAS: targeting the ACE2/Ang-(1-7)/MasR and AT2 receptor pathways|
|Discussion Leaders: Kathryn Sandberg (Georgetown University, Washington DC) and Jan Danser (Erasmus MC, Rotterdam, Netherlands) |
|9:00 am - 9:20 am||Rodrigo Fraga-Silva (Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland)
"ACE2 activators for cardiovascular diseases"
|9:20 am - 9:30 am||Discussion|
|9:30 am - 9:50 am||David Ortiz-Melo (Duke Medical University, Durham, NC, USA)
"Soluble Angiotensin Converting Enzyme 2 as an Additional Source of Blood Pressure Regulation within the Kidney"
|9:50 am - 10:00 am||Discussion|
|10:00 am - 10:20 am||Emma Jones (Monash University, Melbourne, Australia)
"Pharmacology of novel AT2 receptor agonists"
|10:20 am - 10:30 am||Discussion|
|10:30 am - 10:50 am||Gerry Wagenaar (Leiden University Medical Center, Leiden, Netherlands)
"Intervening in AT2 signalling attenuates hyperoxia-induced lung and heart injury in newborn rats"
|10:50 am - 11:00 am||Discussion|
|11:00 am - 12:30 pm||Poster Session II|
|Coffee will be served in the poster area from 11:00 am - 11:30 am|
|1:30 pm - 2:30 pm||New developments and signaling in the RAS|
|Discussion Leaders: Alan Daugherty (University of Kentucky, Lexington, KY) and Johannes Stegbauer (UKD, Dusseldorf, Germany)|
|1:30 pm - 1:50 pm||Eva Königshausen (UKD, Dusseldorf, Germany)
"Ang II promotes beta-arrestin 2 mediated endocytosis in podocytes"
|1:50 pm - 2:00 pm||Discussion|
|2:00 pm - 2:20 pm||TBA|
|2:20 pm - 2:30 pm||Discussion|
|2:30 pm - 3:00 pm||Evaluation Period|
|Fill out GRS Evaluation Forms|
|3:00 pm||Gordon Research Seminar ends. For those attending the associated Gordon Research Conference, please check in at the GRC Office beginning at 4:00 pm.|
Last Updated: December 6, 2013